TP53I3: A Promising Drug Target and Biomarker for the Treatment of Cancer

Target Name: TP53I3

NCBI ID: G9540

TP53I3: A Promising Drug Target and Biomarker for the Treatment of Cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 20 million new cases and 5.5 million deaths in 2019 alone. The discovery of genetic mutations, such as those in the TP53 gene, has led to the development of new treatments and targeting drugs for cancer. TP53I3, also known as TP53I3 variant 2, is a genetic mutation that has been identified in many types of cancer. In this article, we will explore the significance of TP53I3 as a drug target and biomarker for cancer treatment.

The TP53 Genome

The TP53 gene is a tumor suppressor gene that plays a crucial role in maintaining genomic stability. It is one of the most commonly mutated genes in cancer, with over 10% of all cancer mutations occurring in the TP53 gene. The TP53 gene is located on chromosome 17 and has four splice variants, I3, II3, III, and IV. The I3 variant is the most common and has the highest frequency, accounting for approximately 70-80% of all TP53 mutations.

The Role of TP53I3 in Cancer

The TP53I3 gene mutation has been associated with the development and progression of many types of cancer, including breast, ovarian, and colorectal cancers. Studies have shown that individuals with TP53I3 mutations have a higher risk of developing cancer and may also have a more aggressive cancer profile compared to individuals without the mutation.

In addition to its association with cancer, TP53I3 has also been shown to play a role in apoptosis, a critical mechanism that regulates cell death and is often disrupted in cancer. The TP53I3 gene has been shown to promote apoptosis in cancer cells, which may contribute to their enhanced sensitivity to chemotherapy and radiation.

Drug Targeting

The discovery of TP53I3 as a drug target has led to the development of new treatments for cancer. Drugs that target the TP53I3 gene have been shown to inhibit its activity and prevent cancer cells from dividing and undergoing apoptosis. One such drug is the TP53 inhibitor, NEDD8A, which has been shown to inhibit the activity of TP53I3 and reduce the sensitivity of cancer cells to chemotherapy in both human and animal models.

Biomarker

As a potential biomarker for cancer, TP53I3 can be used to monitor the effectiveness of cancer treatments and track disease progression. For example, individuals with TP53I3 mutations may have a more aggressive cancer profile, and the activity of TP53I3 inhibitors can be used to determine the effectiveness of cancer treatments.

Conclusion

TP53I3 is a genetic mutation that has been associated with the development and progression of many types of cancer. Its role in promoting apoptosis and its association with cancer have made it an attractive drug target for cancer treatment. The development of TP53I3 inhibitors, such as NEDD8A, has shown promise in clinical trials and may lead to new treatments for cancer. As a potential biomarker, TP53I3 may also be used to monitor the effectiveness of cancer treatments and track disease progression. Further research is needed to fully understand the role of TP53I3 in cancer and its potential as a drug target and biomarker.

Protein Name: Tumor Protein P53 Inducible Protein 3

Functions: Catalyzes the NADPH-dependent reduction of quinones (PubMed:19349281). Exhibits a low enzymatic activity with beta-naphthoquinones, with a strong preference for the ortho-quinone isomer (1,2-beta-naphthoquinone) over the para isomer (1,4-beta-naphthoquinone). Also displays a low reductase activity for non-quinone compounds such as diamine and 2,6-dichloroindophenol (in vitro) (PubMed:19349281). Involved in the generation of reactive oxygen species (ROS) (PubMed:19349281)

More Common Targets